Clinical Trial Update: Glulisine + Lantus in Type I Patients [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the combination of insulin glulisine and insulin glargine (Lantus) in patients with Type 1 diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Apidra (insulin glulisine)
• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED